英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
popularized查看　popularized　在百度字典中的解释百度英翻中〔查看〕
popularized查看　popularized　在Google字典中的解释Google英翻中〔查看〕
popularized查看　popularized　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Advanced and metastatic prostate cancer: ESMO Clinical . . .
    This includes metastatic castration-sensitive prostate cancer (mCSPC), non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-resistant prostate cancer (mCRPC) The management of early-stage disease is covered in the ESMO CPG for local and locoregional prostate cancer 1
  • Niraparib and abiraterone acetate plus prednisone for HRR . . .
    We hypothesized that PARP inhibition within 6 months of starting androgen deprivation therapy for metastatic castration-sensitive prostate cancer (mCSPC) could be effective and improve
  • Metastatic castration-resistant prostate cancer (mCRPC)
    Metastatic prostate cancer happens when the cancer spreads from the prostate to other parts of the body Sometimes the cancer spreads and hormone therapy helps control it This is called metastatic castration-sensitive prostate cancer (mCSPC) If the cancer spreads and no longer responds to hormone therapy medicines, it's considered mCRPC
  • Advanced Prostate Cancer: AUA SUO Guideline (2026)
    The management of advanced prostate cancer is rapidly evolving To assist in clinical decision-making, evidence-based guideline statements were developed to provide a rational basis for evidence-based treatment This guideline covers advanced prostate cancer, including disease stages that range from prostate-specific antigen (PSA) recurrence after exhaustion of local treatment options to
  • Advanced Prostate Cancer Update: Adding PARP Inhibitor To . . .
    Patients with metastatic castration-sensitive prostate cancer (mCSPC), who have specific genetic mutations, were found to have improved survival by using a targeted treatment called PARP inhibitors combined with standard therapy with an androgen receptor (AR) pathway inhibitor The findings came
  • Metastatic Castration-Sensitive Prostate Cancer: Optimizing . . .
    Further incremental progress in the outcome of patients with mCSPC came from the addition of novel agents, docetaxel or abiraterone, to ADT for more aggressive up-front treatment of metastatic prostate cancer
  • Advanced and metastatic prostate cancer: ESMO Clinical . . .
    This includes metastatic castration-sensitive prostate cancer (mCSPC), non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-resistant prostate cancer (mCRPC) The management of early-stage disease is covered in the ESMO CPG for local and locoregional prostate cancer 1
  • Prostate Cancer, Version 3. 2026 - jnccn. org
    Abstract The NCCN Guidelines for Prostate Cancer provide a framework on which to base decisions for patients with prostate cancer across the dis-ease spectrum The Guidelines sections included in this article focus on metastatic castration-sensitive prostate cancer (mCSPC), nonmeta-static castration-resistant prostate cancer (CRPC), and metastatic CRPC (mCRPC) For patients with mCSPC, disease
  • Truqap recommended by FDA Advisory Committee for PTEN . . .
    The US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) has recognised a favourable benefit risk profile for AstraZeneca’s Truqap (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT) for the treatment of patients with PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC), based on the CAPItello-281 Phase III trial
  • TALZENNA Plus XTANDI Significantly Improves Radiographic . . .
    Prostate cancer is the second most common cancer in men worldwide, with an estimated 1 4 million new cases diagnosed globally in 2022 1 and 330,000 new cases anticipated in the United States in 2026 2 mCSPC, is a form of advanced prostate cancer that has spread beyond the prostate but is still sensitive to androgen inhibition 3 Despite recent





中文字典-英文字典  2005-2009